Ardelyx Inc. (41X)
Summary
41X Chart
New Strong Sell Stocks for October 7th
ARDX, LUV and COLL have been added to the Zacks Rank #5 (Strong Sell) List on October 7th, 2026.
Ardelyx Targets $500M Revenue This Year, Profitability by 2027
Ardelyx NASDAQ: ARDX expects to generate close to $500 million in revenue this year and reach profitability in 2027, supported by continued growth of its IBS-C treatment IBSRELA and hyperphosphatemia treatment XPHOZAH, executives said at a Morgan Stanley event.
Ardelyx, Inc. (ARDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Ardelyx, Inc. (ARDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Ardelyx Inc. (41X) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ardelyx Inc. ever had a stock split?
Ardelyx Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael G. Raab CEO | XSTU Exchange | 039697107 CUSIP |
| US Country | 489 Employees | - Last Dividend | - Last Split | 19 Jun 2014 IPO Date |
Overview
Ardelyx, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines targeting gastrointestinal and cardiorenal therapeutic areas. The company's efforts are primarily focused on addressing the needs of patients in the United States and internationally. Ardelyx was originally established as Nteryx, Inc. and underwent a name change to Ardelyx, Inc. in June 2008. With its foundation in 2007 and headquarters situated in Waltham, Massachusetts, Ardelyx is at the forefront of developing potential treatments for various conditions related to the gastrointestinal tract and renal-cardiac health.
Products and Services
Ardelyx, Inc. is engaged in the development of a range of therapeutic products, including:
- Tenapanor: This is the lead product candidate of Ardelyx, aiming at treating patients suffering from irritable bowel syndrome with constipation (IBS-C). Tenapanor shows promise in alleviating symptoms associated with IBS-C, demonstrating Ardelyx's focus on addressing gastrointestinal disorders.
- XPHOZAH (Phase III): Currently in Phase III clinical trial, XPHOZAH is developed to reduce serum phosphorus in adults suffering from chronic kidney disease (CKD) on dialysis, or those with hyperphosphatemia. This treatment is indicative of Ardelyx's dedication to advancing care in the cardiorenal therapeutic area.
- RDX013: This potassium secretagogue is designed for the treatment of elevated serum potassium, or hyperkalemia, a frequent complication among patients with kidney and/or heart failure. RDX013 embodies the company's efforts to tackle key issues in cardiorenal health through innovative therapeutic solutions.
- RDX020: Targeted towards adult patients with metabolic acidosis, a serious electrolyte disorder, RDX020 is another testament to Ardelyx's commitment to addressing complex cardiorenal conditions.
In addition to developing these pioneering treatments, Ardelyx has forged strategic agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. These partnerships are focused on the development and commercialization of tenapanor in their respective territories, further illustrating Ardelyx's efforts to bring its innovative solutions to a global market.
Contact Information
